Should patients stay on beta-blockers more than one year after a heart attack? The team behind the ABYSS clinical trial explored that very question, presenting its data at ESC Congress 2024.

ESC's annual meeting is always one of the world's largest gatherings of cardiologists and other cardiology professionals. This year's 4-day event will be no different. 

The nine-minute flight was a complete success. Prior Blue Origin space tourism missions have included everyone from Bezos himself to Star Trek actor William Shatner.

The new interventional device from Renata Medical is designed to expand as young patients age, providing long-term relief. 

Insulet's Omnipod 5 Automated Insulin Delivery System was already cleared to help patients manage type 1 diabetes. 

The new AUC document was designed to help care teams know when and how to perform imaging-based cardiovascular evaluations on patients undergoing nonemergent, noncardiac surgery.

Brittany Nicole Weber, MD, PhD, detailed new research into the benefits of screening for cardiovascular disease in CT scans not specifically ordered for that purpose. The rise of AI has helped make opportunistic screening a huge trend in both cardiology and radiology. 

The self-expanding Acurate Prime Aortic Valve System was designed with improved valve positioning in mind. According to Boston Scientific, it it will be available in more sizes than the company's previous TAVR device to ensure it can treat as many heart patients as possible. 

Heart issues are the No. 1 cause of death for liver transplant patients. Screening patients for signs of CAD is one way care teams can help keep such complications to a minimum. 

The Cardiovascular Research Foundation has announced 10 late-breaking clinical trials and 15 late-breaking clinical science sessions for TCT 2024 in Washington, DC. Topics will include TAVR and other structural heart procedures, artificial intelligence and much more.